- Home
- GKOS vs PDFS Comparison
GKOS vs PDFS Comparison
Compare GKOS & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- PDFS
- Stock Information
- Founded
- GKOS 1998
- PDFS 1992
- Country
- GKOS United States
- PDFS United States
- Employees
- GKOS N/A
- PDFS N/A
- Industry
- GKOS Medical/Dental Instruments
- PDFS EDP Services
- Sector
- GKOS Health Care
- PDFS Technology
- Exchange
- GKOS Nasdaq
- PDFS Nasdaq
- Market Cap
- GKOS 5.1B
- PDFS N/A
- IPO Year
- GKOS 2015
- PDFS N/A
- Fundamental
- Price
- GKOS $96.63
- PDFS $18.76
- Analyst Decision
- GKOS Strong Buy
- PDFS Strong Buy
- Analyst Count
- GKOS 13
- PDFS 3
- Target Price
- GKOS $155.00
- PDFS $35.33
- AVG Volume (30 Days)
- GKOS 1.0M
- PDFS 256.3K
- Earning Date
- GKOS 04-30-2025
- PDFS 05-08-2025
- Dividend Yield
- GKOS N/A
- PDFS N/A
- EPS Growth
- GKOS N/A
- PDFS 25.00
- EPS
- GKOS N/A
- PDFS 0.10
- Revenue
- GKOS $383,481,000.00
- PDFS $179,465,000.00
- Revenue This Year
- GKOS $27.84
- PDFS $18.10
- Revenue Next Year
- GKOS $27.99
- PDFS $18.98
- P/E Ratio
- GKOS N/A
- PDFS $187.60
- Revenue Growth
- GKOS 21.85
- PDFS 8.22
- 52 Week Low
- GKOS $77.91
- PDFS $15.91
- 52 Week High
- GKOS $163.71
- PDFS $39.70
- Technical
- Relative Strength Index (RSI)
- GKOS 50.06
- PDFS 49.39
- Support Level
- GKOS $87.17
- PDFS $16.62
- Resistance Level
- GKOS $98.86
- PDFS $17.73
- Average True Range (ATR)
- GKOS 5.59
- PDFS 1.18
- MACD
- GKOS 1.78
- PDFS 0.28
- Stochastic Oscillator
- GKOS 88.89
- PDFS 79.83
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.